The exogenous expression of the truncated forms of CCDC170 in ER+ BC cells results in enhanced growth and tamoxifen resistance, which suggest a role for ER-CCDC170 fusions in endocrine therapy resistance [29,37]. The gene discussed is ESR1; the disease is breast cancer.